companydata.dkcompanydata.dk

K/S BI BIOMEDICAL VENTURE IV: Financial statements 2017

CVR: 28301022

Source: annual report 2017, Danish Business Authority

01/01/2017 – 31/12/2017

K/S BI BIOMEDICAL VENTURE IV (CVR 28301022) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK -913,000 and a net result of DKK -915,000 compared with DKK -27,494,000 the year before. Equity in the 2017 report amounted to DKK 40,712,000. The solvency ratio was 100%.

Gross Profit
DKK -913,000
Profit/Loss
DKK -915,000
Equity
DKK 40,712,000
Total Assets
DKK 40,712,000

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2017--913K-915K40.7M-
2016--27.5M-27.5M42.3M-
2015-66.3M66.3M179.1M-
2014-20.8M20.8M125.8M-
2013-3.2M3.2M127.5M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on K/S BI BIOMEDICAL VENTURE IV

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2017

K/S BI BIOMEDICAL VENTURE IV: The 2016 annual report is outMay 10, 2017

K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2016. Gross profit came to DKK -27,492,000, and the net result was DKK -27,494,000.

About K/S BI BIOMEDICAL VENTURE IV

K/S BI BIOMEDICAL VENTURE IV is a Danish company of the type Kommanditselskab based in København K, founded in 2004. The company is registered under the industry Anden finansiel formidling i.a.n.. The management consists of Ahmet Turan Kayhan. The board consists of Andrea Panzieri (chair), Allan Funk Nissen and Ahmet Turan Kayhan. The company is owned by PENSIONSKASSEN FOR TEKNIKUM- OG DIPLOMINGENIØRER and LÆRERNES PENSION, FORSIKRINGSAKTIESELSKAB. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK 0 the year before. Equity in the 2025 report amounted to DKK 8,000.

Source: annual report 2025, Danish Business Authority